Nosebleed News and Research

RSS

Cancer drug could be effective for treating recurrent nose bleeds

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin.

12 Feb 2010

Anticoagulants used to prevent clots in placental blood vessels ineffective, reveals research

Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolve naturally, a potentially life-threatening situation requiring treatment.

7 Dec 2009

Rapidly cooling a person in cardiac arrest may improve chance of survival without brain damage

Rapidly cooling a person in cardiac arrest may improve their chance of survival without brain damage, according to research presented at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

CeloNova BioSciences today announced that the company is submitting to its European Notified Body a request for approval of its new, lime green, 2800 micron size Embozene(TM) Microsphere.

31 Oct 2009

CeloNova BioSciences' Embozene Microspheres receives approval

CeloNova BioSciences, Inc. has received approval from its European regulatory body, the British Standards Institution, to expand the list of medical indications for which Embozene(TM) Microspheres may be used and to add a tenth size of the product.

14 Oct 2009

FDA approves Avastin (bevacizumab) for treatment of glioblastoma multiforme

The U.S. Food and Drug Administration recently approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme (GBM) when this form of brain cancer continues to progress following standard therapy.

7 May 2009

Novel therapeutic approaches for various forms of thrombocytopenia

Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood, were presented December 6 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008

New clinical study will help doctors assess abnormal bleeding

How do you know if you bleed normally? Scientists at The Rockefeller University Hospital's Center for Clinical and Translational Science (CCTS) aim to answer that question more definitively with the launch of an assessment tool designed to help physicians and researchers more accurately determine what is inside and outside the normal range of bleeding symptoms.

3 Nov 2008

Social networking, malaria and philanthropy partnership

Philanthropy just got easier and a lot more accessible to the public thanks to the social networking power of the Internet and a ground-breaking partnership between a young British entrepreneur, a global health think tank and an African medical research institute.

20 Apr 2008

Toddler takes sildenafil in order to survive

A two year old in Britain has a rare condition that causes chronic high blood pressure and must take Viagra to stay alive.

12 Mar 2008

Guidelines for von Willebrand disease diagnosis and management

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health today issued the first clinical guidelines in the United States for the diagnosis and management of von Willebrand Disease (VWD), the most common inherited bleeding disorder.

4 Mar 2008

New guidelines for von Willebrand disease

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, has issued the first clinical guidelines in the United States for the diagnosis and management of von Willebrand Disease (VWD), the most common inherited bleeding disorder.

1 Mar 2008

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

There are estimated to be between 50,000 -- 100,000 individuals in the U.S. diagnosed with chronic Immune Thrombocytopenic Purpura (ITP), an autoimmune disease that dramatically reduces the number of platelets in their blood -- causing bruises, nosebleeds and, sometimes, life-threatening brain hemorrhages.

29 Nov 2007

Paramedics can provide an effective alternative to standard ambulance service in the community

Paramedics with extended skills can provide a safe and effective alternative to standard ambulance transfer and hospital treatment for older people with a minor injury or illness, finds a study published on bmj.com today.

8 Oct 2007

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline has announced the initiation of a global, open-label, single group trial that will assess the efficacy, safety and tolerability of PROMACTA (eltrombopag olamine) in patients previously treated for chronic idiopathic thrombocytopenic purpura (ITP).

15 Apr 2007

New blood thinner thrombin-receptor antagonist may work without bleeding risk

When studying a new blood thinner, one of the first signs the drug is working is seeing a slight increase in minor bleeding, nose bleeds and bruising, an inconvenient side effect of preventing the blood clots that are the leading cause of heart attack and stroke.

3 Apr 2007

FDA approves Omnaris, new hay fever drug

The U.S. Food and Drug Administration (FDA) has announced the approval of Omnaris (ciclesonide) nasal spray, a new drug for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis, commonly known as hay fever, in adults and children 12 years of age and older.

23 Oct 2006

Chemical dump in Ivory Coast - WHO provides public health support

The first members of WHO's international team arrived in Abidjan this week to support the Ministry of Health in dealing with an environmental health emergency caused by toxic waste.

18 Sep 2006

Combination of salmeterol and fluticasone propionate cuts inflammatory cells in chronic obstructive pulmonary disease

The combination of two existing clinical treatments, salmeterol and fluticasone propionate, can significantly reduce inflammatory cells in the airways of current and former smokers being treated for moderate to severe chronic obstructive pulmonary disease (COPD).

4 Apr 2006